Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
Dementia01:30

Dementia

523
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
523
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Plasma and CSF adiponectin levels in biomarker-confirmed Alzheimer's disease: A cross-sectional study in a tertiary memory clinic.

Metabolic brain disease·2026
Same author

Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression.

Molecular psychiatry·2026
Same author

Copper isotope shifts in biofluids track Alzheimer's pathology.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Anti-amyloid immunotherapies in Alzheimer's disease: Are future prescribers prepared? Insights of a French national survey.

Journal of Alzheimer's disease : JAD·2026
Same author

Tanycytic degeneration impairs tau clearance and contributes to Alzheimer's disease pathology.

Cell press blue·2026

Related Experiment Video

Updated: Jan 16, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.1K

Treatment for Alzheimer's disease.

Nick C Fox1, Christopher Belder2, Clive Ballard3

  • 1Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute at UCL, University College London, London, UK.

Lancet (London, England)
|September 25, 2025
PubMed
Summary

This study offers practical guidance for managing Alzheimer's disease symptoms using existing and new treatments, including anti-amyloid monoclonal antibodies, to improve patient quality of life.

More Related Videos

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.0K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.5K

Related Experiment Videos

Last Updated: Jan 16, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.1K
Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.0K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.5K

Area of Science:

  • Neurology
  • Geriatrics
  • Pharmacology

Background:

  • Evidence for Alzheimer's disease (AD) treatments has grown over 30 years.
  • Current pharmacological and non-pharmacological strategies show limited stringent efficacy evidence.
  • Integrating novel therapies with existing care presents a clinical challenge.

Purpose of the Study:

  • To provide practical advice on prioritizing treatments for cognitive and non-cognitive AD symptoms.
  • To discuss the integration of anti-amyloid monoclonal antibodies into dementia care.
  • To assess the potential of monoclonal antibodies to improve patients' quality of life.

Main Methods:

  • Review of current evidence on Alzheimer's disease management strategies.
  • Analysis of the approval status and clinical integration of anti-amyloid monoclonal antibodies.
  • Synthesis of recommendations for holistic patient care.

Main Results:

  • Existing treatments for Alzheimer's disease symptoms have limitations in proven efficacy.
  • Anti-amyloid monoclonal antibodies represent a new frontier in Alzheimer's treatment.
  • Seamless integration of novel therapies with established care is crucial.

Conclusions:

  • Prioritizing evidence-based strategies is essential for managing Alzheimer's disease.
  • Anti-amyloid monoclonal antibodies offer potential benefits for patient quality of life.
  • A holistic approach integrating new and existing treatments is recommended for optimal Alzheimer's care.